EUVIMEDEUVIMED entdecken
Kohortenstudie

Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study

Kai-Yuan Jiang iD, Wen-Long Hu, Shi-Xiang Liu, Lei Wang, Jie Li, Lin Lin, Heng-Tao Lin, Jun-Jie Wang, Long-Qi Chen, Dong Tian iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70214 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Kai-Yuan Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: The Undergraduate Innovation and Entrepreneurship Training Program of Sichuan Province, China, The 2023 Clinical Research Fund, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There remains uncertainty regarding the efficacy of adjuvant immunotherapy following neoadjuvant therapy and surgery in patients with esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the prognostic value of adjuvant immunotherapy and immunochemotherapy (ICT) for ESCC patients. This retrospective cohort study reviewed ESCC patients who underwent neoadjuvant therapy followed by radical esophagectomy. Postoperative adjuvant therapy included chemotherapy, chemoradiotherapy (CRT), immunotherapy, and ICT. Overall survival (OS) and disease‐free survival (DFS) were compared using the Kaplan–Meier method, and independent prognostic factors were identified via multivariate Cox regression analysis. A total of 690 patients were included, of whom 176 (25.5%) received adjuvant therapy, with 61, 37, 45, and 33 patients receiving chemotherapy, CRT, immunotherapy, and ICT, respectively. Among the adjuvant therapy group, both immunotherapy and ICT significantly improved OS compared to CRT ( p < .001 and p = .011, respectively). For DFS, the immunotherapy group showed significantly better survival than the chemotherapy and CRT groups ( p = .042 and p < .001, respectively). Multivariate analysis identified immunotherapy and ICT as independent favorable prognostic factors for both OS and DFS (all p < .05). Furthermore, patients receiving perioperative immunotherapy achieved superior OS and DFS than those receiving other treatment regimens (all p < .05). Our findings suggest potential benefits of immunotherapy and ICT as adjuvant therapy for ESCC. It also indicates that perioperative immunotherapy may have broader applicability beyond current recommendations and could contribute to optimizing treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsImmunotherapyHumansFemaleRetrospective StudiesMaleMiddle AgedAgedEsophagectomyPrognosisNeoadjuvant TherapyChemotherapy, AdjuvantAdultDisease-Free SurvivalTreatment OutcomeKaplan-Meier Estimate

Stichwörter der Autor:innen

adjuvant therapyesophageal squamous cell carcinomaimmunochemotherapyimmunotherapyprognosis

Autor:innen und Institutionen

  • Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • College of Clinical Medicine, North Sichuan Medical College, Nanchong, China.
  • West China School of Medicine, Sichuan University, Chengdu, China.
  • Department of Thoracic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

ORCID-Profile: Kai-Yuan Jiang, Dong Tian

Förderung

  • The Undergraduate Innovation and Entrepreneurship Training Program of Sichuan Province, China
  • The 2023 Clinical Research Fund, West China Hospital, Sichuan University

Zitieren

APA

Jiang, K. Y., Hu, W. L., Liu, S. X., Wang, L., Li, J., Lin, L., Lin, H. T., Wang, J. J., Chen, L. Q., & Tian, D. (2026). Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study. International Journal of Cancer. https://doi.org/10.1002/ijc.70214

Vancouver

Jiang KY, Hu WL, Liu SX, Wang L, Li J, Lin L, et al. Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study. International Journal of Cancer. 2026. doi:10.1002/ijc.70214

BibTeX
@article{Jiang2026,
  author = {Jiang, Kai-Yuan and Hu, Wen-Long and Liu, Shi-Xiang and Wang, Lei and Li, Jie and Lin, Lin and Lin, Heng-Tao and Wang, Jun-Jie and Chen, Long-Qi and Tian, Dong},
  title = {Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70214}
}
Kostenlos starten →